SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as the memory sector rallies on AI-driven supply constraints and rumors of a potential geopolitical peace deal, fueling community speculation about a significant price run-up before earnings. While investors debate the sustainability of record data center infrastructure spending, sentiment remains highly bullish with active discussions regarding PT upgrades, historical cyclical shifts, and institutional accumulation.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is facing significant volatility and investor frustration as market participants debate its valuation relative to the upcoming SpaceX IPO, with many questioning the fund's lack of transparency regarding management actions and recent dilution. While some investors see the current pullback as a bargain opportunity to gain exposure to a basket of high-growth tech firms including Anthropic and OpenAI, others are concerned that the fund's premium is evaporating now that direct access to its largest holdings is becoming possible.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Investors are actively debating the sustainability of the semiconductor rally as SOXL experiences heightened volatility, with community sentiment split between those viewing recent pullbacks as prime accumulation opportunities and others concerned about significant leverage decay and potential market correction. The conversation is largely centered on gauging new support levels amid shifting geopolitical narratives and the highly anticipated upcoming IPO of SpaceX, which traders are closely watching for its broader impact on market liquidity.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the company's $180 million stock offering and the recent Phase 3 trial success for its hereditary angioedema therapy, Lonvo-z. While the community is actively debating the dilution impact of the offering against the stock's long-term commercial potential, many are pointing to institutional backing and a significant short interest as catalysts for potential future price volatility.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently driving intense market activity following its massive IPO, with investors debating the sustainability of its multi-trillion dollar valuation amidst limited float and high-profile retail interest. Community discourse remains deeply divided between those viewing it as a historic growth opportunity and skeptics concerned about long-term profitability and the risks of a potential post-IPO volatility spike.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is seeing a surge in investor interest and trading volume following the official reveal of its collaborative 800V power delivery architecture at NVIDIA's AI Factory MGX ecosystem showcase during Computex. The community is heavily focused on the company's long-term potential as a critical AI infrastructure supplier, with many active traders debating the stock's valuation versus its strategic role in improving data center efficiency.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

Direxion Daily MU Bull 2X Shares ($MUU) is surging as investors aggressively pile into Micron-linked leveraged plays to capture the ongoing memory super cycle and high-bandwidth memory (HBM) demand. The community is actively debating the merits of holding this leveraged ETF long-term versus day trading, with many participants citing analyst upgrades and long-term supply constraints as primary drivers for the bullish sentiment.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending as investors weigh its pivot from a bitcoin-focused miner to an AI infrastructure and data center operator, an evolution bolstered by community discussions surrounding a potential long-term decoupling from bitcoin price volatility. While retail sentiment remains polarized between frustration over management's execution and optimism regarding the company's energy assets and institutional backing, trading activity is dominated by heavy options volume and speculative interest in the timing of hyperscaler tenant deals.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market sentiment for the S&P 500 is surging as investors react to a high-profile, non-binding memorandum of understanding between the U.S. and Iran, with traders actively debating the deal's long-term viability versus its immediate bullish impact on risk assets. Community discussions remain polarized, pitting optimism over potential interest rate cuts and de-escalation against skepticism regarding the deal's specifics and the broader sustainability of the current rally.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing high volatility as investors weigh strong underlying profitability against persistent selling pressure, leading to significant community debate over whether the stock is a deep-value turnaround play or a long-term value trap. The stock has become a primary focal point for traders debating the impact of recent institutional accumulation and aggressive insider sentiment, with many actively discussing its positioning against streaming competitors in the current market climate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?

KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 211 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). These data highlight the significant unmet needs...

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...

Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to receive...

KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High  - Here's Why

KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Still a Buy...

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...

KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright

HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Friday...

KalVista Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule therapies for diseases with significant unmet medical needs. It concentrates on developing oral medicines, particularly targeting rare conditions such as hereditary angioedema (HAE), a genetic disorder characterized by severe swelling episodes. EKTERLY (sebetralstat) is its primary therapy, designed as an on-demand oral treatment that offers an alternative to injectable options. The company’s research pipeline also includes programs exploring oral Factor XIIa inhibitors and additional treatments for conditions such as thrombosis and inflammation. Its operations are centered on advancing clinical development and leveraging proprietary protease inhibitor technology to expand treatment options across rare disease indications.

KALVKalVista Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALV News